Back to search results
NCT04487041

Tfh Dysfunction in HIV and Aging

Active, Not Recruiting
PHASE4Ages 18+InterventionalBasic science
University of Miami
~400 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:Standard dose influenza vaccinationHigh dose influenza vaccination

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in HAI antibody response
Measured over Baseline to Month 6 (post standard dose flu vaccination), Baseline to Month 18 (post high-dose flu vaccination)
+2 more outcomes measured

Conditions

Human Influenza

Explore related trials

HIV InfectionInfluenzaCD4 GeneHIV Infection

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Savita Pahwa, MD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

HIV infection, as documented by any licensed ELISA test kit. Participants on ART as a result of prior HIV documented infection will not be required to provide proof of diagnosis of HIV infection.
Additional criteria for HIV positive
Documented negative HIV test at the time of study entry, either by any licensed ELISA. 3. For all participants:

What this trial measures

  • Change in HAI antibody responseBaseline to Month 6 (post standard dose flu vaccination), Baseline to Month 18 (post high-dose flu vaccination)

    Change in mean titers of Hemagglutination inhibition (HAI) antibody response will be measured using serum sample.

  • Change in neutralization antibody responseBaseline to Month 6 (post standard dose flu vaccination), Baseline to Month 18 (post high-dose flu vaccination)

    Change in mean titers of neutralization antibody response will be measured using serum sample.

  • Percentage of Participants with Vaccine ResponseMonth 13 (1 month post high-dose flu vaccination)

    Percentage of participants that are vaccine responders and non-responders will be reported. Response is evaluated using seroconversion to the flu vaccine using serum sample.